Sanofi Consumer Healthcare India Limited (BSE: 544250 | NSE: SANOFICONR) has reported a strong set of numbers for the fourth quarter and full year ended December 31, 2025, driven by robust domestic growth and a sharp rise in exports. The company posted Q4 revenue of ₹2,510 million, up 47% year-on-year. Domestic sales grew 23%, supported by the relaunch of recalled products, while export sales surged 9.3 times on a low base. Profit after tax rose 50% to ₹665 million during the quarter.
For the full year FY25, revenue stood at ₹8,784 million, marking a 21% growth over the previous year. Domestic sales increased 7%, while export sales jumped 158% due to a low base effect. Annual profit after tax rose 33% to ₹2,401 million. The company also declared a dividend of ₹75 per share. Managing Director Himanshu Bakshi said the performance reflects strength in the core portfolio and disciplined execution. Chairman Amit Jain said sustained growth and improved product mix enabled the company to reward shareholders.
In Kolkata, trade sources said improved product availability following the relaunch has led to better off-take across pharmacies. Retailers noted steady demand for key brands in allergy, digestive wellness and pain care segments, supporting the company’s eastern region growth momentum.
